BiomeSense

Executive Summary

BiomeSense is a San Francisco-based biotechnology company developing advanced microbiome analytics technology to enable real-time, longitudinal insights into the gut microbiome. Founded in 2019, the company combines novel hardware with AI-enabled bioinformatics to unlock the personalized medicine potential of the microbiome. By providing continuous monitoring and data-driven analysis, BiomeSense aims to transform healthcare, research, and diagnostics. While specific funding and commercial milestones are undisclosed, the company's approach addresses a critical gap in microbiome science—moving from static snapshots to dynamic, actionable insights. This positions BiomeSense at the forefront of a rapidly growing field with significant applications in disease prevention, treatment optimization, and wellness. However, as a private company with limited public information, execution risk remains high. The success of BiomeSense hinges on its ability to validate its technology through clinical partnerships, secure funding, and achieve regulatory clearance. Given the early-stage nature and lack of disclosed traction, we assign a moderate conviction score.

Upcoming Catalysts (preview)

• Q4 2026Announcement of strategic partnership with a pharmaceutical or diagnostic company for clinical validation of the BiomeSense platform40% success
• Q2 2027Launch of a commercial product or beta version of the real-time microbiome monitoring device30% success
• Q3 2026Series A or B funding round to scale operations and support clinical trials50% success